D. Western Therapeutics Institute, Inc.
Regarding U.S. Distribution Partnership and Launch Timing for Bondlido
Regarding Bondlido's U.S. distribution partnership and launch timing: the sales license agreement is expected to be signed in October, and the launch is expected in Q4 2026. Renegotiation of contract terms is taking additional time; revenue impact is uncertain but may affect dividends depending on terms. Impact on the fiscal year ending December 2026 is undecided.
Key Figures
- Timing of Bondlido sales license agreement: October
- Launch timing: Q4 2026
- Earnings guidance for fiscal year ending December 2026: Unknown
AI要約
Business and Partnership Highlights
The focus is on advancing a U.S. distribution partnership and launch for Bondlido. Based on basic agreements with MedRecs and Terrain Pharmaceuticals, adjustments to the sales license agreement terms are underway. Currently, signing of the agreement is targeted for October; however, renegotiation of terms is taking additional time, and the launch timing has been revised to Q4 2026. There is a possibility of receiving a certain share of proceeds as performance-based payments, but the impact on the fiscal year ending December 2026 remains undetermined.
Market Outlook and Investor Impact
The U.S. market size for lidocaine patches is estimated at approximately 44 billion yen as of 2025, and Bondlido aims to expand the market building on Lidoderm. Delays in launch timing and changes in terms are short-term uncertainties, but the product could become a long-term revenue source. Depending on contract terms, the company may receive revenue distributions, so future contract progress and successful launch will likely affect financial results.
D. Western Therapeutics Institute, Inc.
Company overview · Stock price · Financial data · All IR
